Updated Palestinian EDL (Core List) and CDL
Vial: 0.25% Injection for spinal anesthesia: 0.5%
in 4‐ml amp to be mixed with 7.5% glucose solution
Lidocaine HCl + Epinephrine (adrenaline)
1.3 Preoperative medication and sedation for short-term procedures
2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY MEDICINES (NSAIMs), MEDICINES USED TO TREAT GOUT AND DISEASE MODIFYING AGENTS IN RHEUMATOID DISORDERS (DMARDs)
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
Injection: 10 mg in 1ml ampoule Tablet (prolonged release): 10 mg;
2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS E03002104
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
Injection: 20%. 10 mL Injection: 1 mg (sulfate) in 1‐ml
Tablet: 250 mg Powder for injection: 500 mg
Injection: 1%. Injection: 0.4 mg/ mL in 1‐ml
5. ANTICONVULSANTS/ANTIEPILEPTICS E05003104
Tablet: 500 mg + 125 mg Oral Liquid (Suspension):400 mg
Powder for injection: 1 g in vial. Powder for injection: 900 mg
benzylpenicillin (= 1.2 million IU) in 5 -ml.
Injection: 10 million IU Suspension (Powder for
reconstitution with water): 250 mg/5 mL. 100 mL
Injection: 1 gm in a vial Powder for oral liquid: 250 mg (as
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors
6.5.1 Antiamoebic and antigiardiasis medicines
Hydroxychloroquine as phosphate or sulfate
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines
8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN PALLIATIVE CARE
8.1 Immunosuppressive and Immunostimulants
Injection: 1 gram in vial Powder for injection: 10 000 IU in
Injection: 2000 I.U Solution: 50 mg/ ml elemental iron
Injection: 100 mg /5mg IU Injection: 1000 mcg in 1‐ml
10.3 Other medicines for haemoglobinopathies
11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES
Tablet: 5 mg Oral liquid (Elixir): 0.05 mg/ml. 60
Tablet: 250 mg. Powder for infusion: 50 mg in
Tablet: 75 mg. Powder for injection: 1.5 million IU
13.3 Anti-inflammatory and antipruritic medicines
13.4 Medicines affecting skin differentiation and proliferation
Calcipotriol 50 mcg/g + Betamethasone 0.5 mg/
Salicylic acid + Benzocaine in a colloidal base.
Powder, 5 Kg. Injection: 0.679 gm\ ml- 100 ml in
Meglumine ioxitalmate + Sodium ioxitalamate
17.1. Antacids & Antiulcer medicines
Aluminium hydroxide gel + Mg trisilicate
Adult supp: 2.7 grams Syrup: 50% + 8% + 5% w/w. 100
Pancreatin ( protease +lipase + amylase)
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
18.5 Insulin and other medicines used for diabetes
Tuberculin, purified protein derivative (PPD)
Infusion : 5%, 100 mL Injection: 250 micrograms in
Poliomyelitis vaccine (Polio Salk vaccine)
Poliomyelitis vaccine (Polio Oral vaccine)
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS E20001208
Tablet: 60 mg. Injection: 50 mg /ml in 2‐ml
21.4 Miotics and anti-glaucoma medicines
Solution (eye drops): 2%, 4% Solution (eye drops): 0.5% (as
24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychotic disorders
24.2.1 Medicines used in depressive disorders
24.2.2 Medicines used in bipolar disorders
24.4 Medicines used for obsessive compulsive disorders
25. MEDICINES ACTING ON THE RESPIRATORY TRACT
Aerosol: 400 micrograms Inhalation (aerosol): 20
micrograms/metered dose Solution for nebulization 0.25
mg/mL. 25 mL. Inhalation (aerosol): 100 micrograms
per dose Respiratory solution for use in
26.Solutions correcting water, electrolyte and acid -base
Solution : 500 ml Injectable solution: 5% (isotonic). 1
Injectable solution: 10% (hypertonic) Injectable solution: 50%
Injectable solution: 20% Injectable solution: 5% + 0.9%. 500
27. VITAMINS, MINERALS AND OTHER NUTRITIONAL SUPPLEMENTS
Nutramigen 425 or alike (hydrolysed cow milk
Phenylalanine- free formula for children
Prosobee or alike (soya protein based formula).
29. SPECIFIC MEDICINES FOR NEONATAL CARE E29001204
Solution for Injection: 0.5 mg/ ml. Injection: 20 mg/ml (equivalent to
10 mg caffeine base/ml). Oral liquid: 20 mg/ml (equivalent to
Parents and Educators Need to be Aware of the Health Risks of Consuming Energy Drinks Prince Edward Island Home and School Federation March 20, 2009 The Prince Edward Island Home and School Federation thanks the provincial“Standing Committee on Social Development,” for the opportunity to forward ourconcerns and ideas on the sale of “energy drinks”. The Federation’s
Therapeutic and Pharmacologic Differences between Medications Used in the Treatment of Bipolar Disorders: Seven-Year UpdateA detailed review was published in 2004 on the sus propiedades terapéuticas en las diferentes fases de los therapeutic properties of the medications used in the trastornos bipolares llevando a proponer un cambio en treatment of bipolar disorders (Tamayo, JM et al. Actas